Strategic Priorities in Cancer Therapy: Navigating the 2026 Cancer Mission Calls
TBC
TBC
Show more
TBC
Industry Contact Point
We provide comprehensive support for researchers and entrepreneurs in the medical technology and healthcare sectors in securing funding from the Horizon Europe program. The goal of the Industry Contact Point for Medical Technologies and Health (ICP MTH) is to foster the development of innovative research and the implementation of breakthrough technological solutions by facilitating access to European grant instruments. .
We provide comprehensive support for researchers and entrepreneurs in the medical technology and healthcare sectors in securing funding from the Horizon Europe program. The goal of the Industry Contact Point for Medical Technologies and Health (ICP MTH) is to foster the development of innovative research and the implementation of breakthrough technological solutions by facilitating access to European grant instruments. .
Show more
The scope of our activities includes:
- assisting in identifying suitable international partners for project collaboration,
- representing Polish institutions at matchmaking and brokerage events,
- organizing thematic trainings and workshops,
- providing individual consultations during the preparation of project proposals.
How Can We Help?
The National Contact Point for Medical Technologies and Health focuses on key research and development areas such as coördinated healthcare and telemedicine, bioinformatics and digital tools supporting therapeutic processes, modern and personalized diagnostics, biomedical engineering and protein therapies, as well as the development of innovative materials for medical applications and advanced technologies for the manufacturing of medicinal products, including advanced therapy medicinal products (ATMPs).
The Horizon Europe Program is the largest research and innovation funding program in the history of the European Union. With a budget of €95.5 billion for the years 2021 – 2027, it offers extensive funding opportunities for projects with high development and implementation potential.
Who Can Benefit from Our Support?
The ICP MTH services are available to: research institutes, universities, public administration entities, large enterprises, SMEs, start-ups, associations, foundations, and international organizations interested in implementing research and innovation projects in the field of health and medical technologies.
Show more
The scope of our activities includes:
- assisting in identifying suitable international partners for project collaboration,
- representing Polish institutions at matchmaking and brokerage events,
- organizing thematic trainings and workshops,
- providing individual consultations during the preparation of project proposals.
How Can We Help?
The National Contact Point for Medical Technologies and Health focuses on key research and development areas such as coördinated healthcare and telemedicine, bioinformatics and digital tools supporting therapeutic processes, modern and personalized diagnostics, biomedical engineering and protein therapies, as well as the development of innovative materials for medical applications and advanced technologies for the manufacturing of medicinal products, including advanced therapy medicinal products (ATMPs).
The Horizon Europe Program is the largest research and innovation funding program in the history of the European Union. With a budget of €95.5 billion for the years 2021 – 2027, it offers extensive funding opportunities for projects with high development and implementation potential.
Who Can Benefit from Our Support?
The ICP MTH services are available to: research institutes, universities, public administration entities, large enterprises, SMEs, start-ups, associations, foundations, and international organizations interested in implementing research and innovation projects in the field of health and medical technologies.
Read the Abstracts from Our Invited Speakers
Cancer Biology
- AllergoOncology: Lessons Learned from the Allergy-Glioblastoma Connection
Aurélie Poli, Luxembourg Institute of Health, LUXEMBOURG
- Cytotoxic NK Cells Impede Response to Checkpoint Immunotherapy in Melanoma with an Immune-Excluded Phenotype
Joanna Poźniak, KU Leuven, BELGIUM
- Inducing Immunogenic Tertiary Lymphoid Structures Across Cancer Types With Dendritic Cell Reprogramming
Camille Chatelain, Lund University, SWEDEN
- The Role of ILC2 in Tissue Homeostasis and Neoplasia
Tim Halim, Cancer Research UK Cambridge Institute, UNITED KINGDOM
Cancer Neuroscience
- Latent Neuropathy in Colorectal Cancer: Implications for Cancer Survivorship
Andrew Shepherd, University of Texas MD Anderson Cancer Center, USA
- Remodelling of the Bone Microenvironment During Cancer Infiltration: Insights from Multiplex Imaging and Spatial Transcriptomics
Christina Møller Andreasen, University of Southern Denmark, DENMARK
- Enteric Nervous System-Derived VIP Restrains Differentiation of LGR5+ Stem Cells Towards the Secretory Lineage Impeding Type 2 Immune Programs
Christoph Klose, Charité – Berlin University Medicine, GERMANY
Cancer Therapy
- Targeting the Dark Matter of Cancer with AI-Designed Mini Binder
Tobias Bald, University of Bonn, GERMANY
- Engineering Nanomedicines for Targeted Neuroimmune Modulation
Helena Florindo, University of Lisbon, PORTUGAL
- Potentiating Immunotherapy of Urological Cancers with Oncolytic Viruses
Gabri van der Pluijm, Leiden University Medical Center, THE NETHERLANDS
- Strategic Priorities in Cancer Therapy: Navigating the 2026 Cancer Mission Calls
Industry Contact Point, Łukasiewicz – PORT, POLAND
- Cancer Neuroscience of Brain Tumors: From Basic Discoveries to Clinical TrialsKEYNOTE SPEAKER
Frank Winkler, Universitätsklinik Heidelberg, GERMANY
- TBC
Sheeba Irshad, King’s College London, UNITED KINGDOM
- The War Against Glioblastoma Needs More Than Standard of Care
Stefaan Van Gool, IOZK Immun-Onkologisches Zentrum Köln, GERMANY
- Uncovering the Spatial Regulation of γδ T Cells: Toward Receptor-Guided Immunotherapy
Jürgen Kuball, University Medical Center Utrecht, THE NETHERLANDS
- Latest Advances in CAR‑T Therapy in Lymphoma: Where Are We and Where Are We Going?
Jarosław Dybko, Lower Silesian Oncology Center in Wroclaw, POLAND
- Expanding CAR Targets to Non Protein Antigens
Sébastien Wälchli, Oslo University Hospital, NORWAY
- TBC
Helen Kakkassery, King’s College London, UNITED KINGDOM
PORT for Business — Company Session
- From Sample to Insight: Advanced Analytics for Oncology Research
Malwina Woźniak, Łukasiewicz – PORT, POLAND
- Beyond glioblastoma — WPD Pharmaceuticals
Mariusz Olejniczak, WPD Pharmaceuticals, POLAND
- The Development of USP7 Inhibitor for Cancer Immunotherapy
Zbigniew Zasłona, Molecule, POLAND
- Leveraging Cancer Biology for Therapeutic Innovation: Clinical and Discovery Advances at Ryvu
Milena Mazan, Ryvu Therapeutics, POLAND
- TBC
Marek Kudła, Ardigen, POLAND
- TBC
Artur Wnorowski, Biotechna, POLAND
- Development of Biological Drugs for Oncological Indications at Mabion
Jakub Knurek, Mabion, POLAND